Reconditioned monocytes are immunomodulatory and regulate inflammatory environment in sepsis

Area of Science:

• Immunology
• Regenerative Medicine
• Cell Therapy

Background:

• Sepsis involves a dysregulated immune response and hyperinflammation, leading to severe illness.
• Mesenchymal stem cells (MSCs) possess immunomodulatory properties evaluated for sepsis therapy.
• Reconditioned monocytes (RM), derived from PBMCs, exhibit both macrophage and MSC-like characteristics.

Purpose of the Study:

• To evaluate the therapeutic potential of reconditioned monocytes (RM) in a preclinical sepsis model.
• To assess the immunomodulatory effects of RM in vitro using peripheral blood mononuclear cells (PBMCs) from sepsis patients.

Main Methods:

• RM were generated from healthy human PBMCs and administered at various stages in a mouse sepsis model.
• Serum cytokine levels (IL-6, MCP-1, IL-10) and survival rates were monitored.
• In vitro studies involved co-culturing RM with PBMCs from sepsis patients to analyze inflammatory markers and reactive oxygen species (ROS) production.

Main Results:

• RM administration in mice reduced serum IL-6, MCP-1, and IL-10 levels, improved hypothermia, and increased survival from 0% to 66% when combined with antibiotics.
• In vitro, RM co-culture with sepsis patient PBMCs reduced ROS production and down-regulated IL-6, IL-8, and IL-10, while up-regulating TGF-β.
• Reduced human leucocyte antigen DR expression on RM facilitated co-culture with patient PBMCs.

Conclusions:

• Reconditioned monocytes (RM) demonstrate significant immunomodulatory effects and enhance survival in a sepsis mouse model.
• RM therapy holds potential for modulating the inflammatory response in sepsis patients.
• RM represent a promising cell-based therapeutic strategy for sepsis treatment.